NCT04027816 is a clinical trial in Neuroaxonal Dystrophy, Infantile, sponsored by Biojiva LLC.

Who is sponsoring NCT04027816?

NCT04027816 is sponsored by Biojiva LLC.

What condition does NCT04027816 study?

NCT04027816 studies Neuroaxonal Dystrophy, Infantile.

Is NCT04027816 still recruiting?

NCT04027816 is currently completed. Last updated 8 April 2022.

Last reviewed 2022-04-08 · How we verify

NCT04027816

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Natural History Study of Infantile Neuroaxonal Dystrophy

Completed Last updated 8 April 2022

What this trial tests

trial in Neuroaxonal Dystrophy, Infantile in 43 participants. Completed in 28 February 2022.

Timeline

17 June 2019

Primary endpoint
14 February 2022

28 February 2022

Quick facts

Lead sponsor	Biojiva LLC
Status	Completed
Study type	OBSERVATIONAL
Enrollment	43
Start date	17 June 2019
Primary completion	14 February 2022
Estimated completion	28 February 2022
Sites	5 locations across Tunisia, Saudi Arabia, China, Egypt, India

Conditions studied

Neuroaxonal Dystrophy, Infantile — all drugs for Neuroaxonal Dystrophy, Infantile →

Sponsor

Biojiva LLC — full company profile →

Who can join

Adults 18 Months to 10, any sex, with Neuroaxonal Dystrophy, Infantile. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a longitudinal and prospective study of the natural history of infantile neuroaxonal dystrophy (INAD).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Treatment of infantile neuroaxonal dystrophy with RT001: A di-deuterated ethyl ester of linoleic acid: Report of two cases.
Adams D, Midei M, Dastgir J, Flora C, et al · · 2020 · cited 17× · PMID 32685351 · DOI 10.1002/jmd2.12116

Verify or expand the search:

Other Biojiva LLC trials

Trials by the same sponsor.

NCT07029945 — A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atroph · Phase 1, PHASE2 · not yet recruiting
NCT04937530 — RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY · Phase 2 · unknown
NCT04762589 — RT001 in Amyotrophic Lateral Sclerosis · Phase 2 · completed
NCT04102501 — A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia · Phase 3 · completed
NCT03570931 — A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy · Phase 2, PHASE3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04027816 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biojiva LLC
Last refreshed: 8 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04027816.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing